The biosimulation market is expected to reach USD 2.88 Billion by 2022 from USD 1.38 Billion in 2017, at a CAGR of 15.9%. Factors such as the increase in R&D investments in the pharmaceutical and biotechnology industries, growing adoption of biosimulation software by regulatory bodies, technologically advanced QSP systems, need to curtail drug discovery and development costs, and growth in the biologics and biosimilars markets are driving the growth of this market
Product launches & upgradations accounted for the largest share of the overall growth strategies followed by key players between 2014 and 2017. Some of the companies that adopted this strategy include Certara, Simulation Plus, Schrödinger, ACD/Labs, and Chemical Computing Group.
The biosimulation market is highly competitive with several big and small players. Prominent players in this market include Certara (US), Simulations Plus (US), Dassault Systèmes (France), Schrödinger (US), ACD/Labs (Canada), Chemical Computing Group (Canada), Physiomics (UK), Evidera (US), In silico biosciences (US), INOSIM Software (Germany), Insilico Biotechnology (Germany), LeadInvent Technologies (India), Rosa (US), Nuventra Pharma (US), and Genedata (Switzerland).
Certara is one of the leading players in the biosimulation market. This leading position of the company can be attributed to its strong brand recognition and extensive product portfolio in the market. The company has a vast presence in North America, Europe, Asia, and Australia. In order to maintain its leading position in the biosimulation market the company focuses on inorganic and organic growth strategies like product launches and upgradations, expansions, acquisitions, and partnerships. For instance, in September 2016, the company acquired d3 Medicine (Australia) to enhance the company’s expertise in the field of modeling and simulation modeling, simulation, and regulatory science powerhouse. Likewise, in October 2017, the company launched Phoenix 8.0 PK/PD Modeling and Simulation software.
Simulation Plus is the second leading player in the global biosimulation market. The company has a vast presence in North America, South America, Europe, and Asia. In order to maintain its leading position in the biosimulation market, the company focuses on research and development activities and product launches. The company invested USD 1.45 million, USD 1.33 million, and USD 0.95 million in R&D activities in 2016, 2015, and 2014, respectively. With its focus on R&D, the company launched version 2.0 of the Membrane Plus simulation software in August 2017. The company‘s efforts towards enhancing its focus on R&D and product offerings will help it to maintain its leading position in the market. The company also focuses on acquisitions and agreements as its growth strategies to expand its business in the global biosimulation market. In June 2017, the company acquired DILIsym Services, Inc. (US), to expand its product portfolio in the field of simulation software and consulting services of drug-induced liver injury.
Biosimulation Market by Product (Software, Molecular Simulation, In House, Contract Services), Application (Clinical Trials, PKPD, ADME), Delivery (Subscription, Ownership), End User (Biotech, Pharma Companies, CROs, Regulatory) - Global Forecast to 2022
630 Dundee Road
Northbrook, IL 60062
USA : 1-888-600-6441
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.SEND ME A FREE SAMPLE